Company intelligence / Profile preview

Serendipity Biosciences

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Platforms offer next-generation, programmable editing (innovations over CRISPR-Cas systems), enabling precise in vivo DNA insertions—including large exons or genes—delivered by adeno-associated virus (AAV) vectors

Therapeutic areas: NeurologyRare DiseasesGastroenterology
Modalities: Gene therapyCRISPR-based therapyBiologicReverse transcriptase editing approaches
Industry: Non-Drug Biotech

Partnerships

No independent partnerships disclosed before acquisition; Arbor Biotechnologies has numerous pharma and biotech partnerships

Beyond the preview

Go deeper on Serendipity Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serendipity Biosciences.

Explore the full profile